Sonothrombolysis for acute ischemic stroke: a systematic review of randomized controlled trials

Edson Bor-Seng-Shu, M.D., Ph.D., Ricardo de Carvalho Nogueira, M.D., Eberval G. Figueiredo, M.D., Ph.D., Eli Faria Evaristo, M.D., Ph.D., Adriana Bastos Conforto, M.D., Ph.D., and Manoel Jacobsen Teixeira, M.D., Ph.D.

Divisions of 'Neurological Surgery and 'Neurology, Hospital das Clinicas, University of Sao Paulo School of Medicine; and 'Instituto Israelita de Ensino e Pesquisa Albert Einstein, Sao Paulo, Brazil

**Object.** Sonothrombolysis has recently been considered an emerging modality for the treatment of stroke. The purpose of the present paper was to review randomized clinical studies concerning the effects of sonothrombolysis associated with tissue plasminogen activator (tPA) on acute ischemic stroke.

**Methods.** Systematic searches for literature published between January 1996 and July 2011 were performed for studies regarding sonothrombolysis combined with tPA for acute ischemic stroke. Only randomized controlled trials were included. Data extraction was based on ultrasound variables, patient characteristics, and outcome variables (rate of intracranial hemorrhages and arterial recanalization).

**Results.** Four trials were included in this study: 2 trials evaluated the effect of transcranial Doppler (TCD) ultrasonography on sonothrombolysis, and 2 addressed transcranial color-coded duplex (TCCD) ultrasonography. The frequency of ultrasound waves varied from 1.8 to 2 MHz. The duration of thrombus exposure to ultrasound energy ranged from 60 to 120 minutes. Sample sizes were small, recanalization was evaluated at different time points (60 and 120 minutes), and inclusion criteria were heterogeneous. Sonothrombolysis combined with tPA did not lead to an increase in symptomatic intracranial hemorrhagic complications. Two studies demonstrated that patients treated with ultrasound combined with tPA had statistically significant higher rates of recanalization than patients treated with tPA alone.

**Conclusions.** Despite the heterogeneity and the limitations of the reviewed studies, there is evidence that sonothrombolysis associated with tPA is a safe procedure and results in an increased rate of recanalization in the setting of acute ischemic stroke when wave frequencies and energy intensities of diagnostic ultrasound systems are used.

(http://thejns.org/doi/abs/10.3171/2011.10.FOCUS11251)

**Keywords** • sonothrombolysis • stroke • tissue plasminogen activator • transcranial color-coded duplex • transcranial Doppler ultrasonography • ultrasound-enhanced thrombolysis

Abbreviations used in this paper: NIHSS = National Institutes of Health Stroke Scale; TCCD = transcranial color-coded duplex; TCD = transcranial Doppler; tPA = tissue plasminogen activator; TRUMBI = Transcranial Low-Frequency Ultrasound-Mediated Thrombolysis in Brain Ischemia.

Systemic administration of tPA has been established as an effective therapy for improving neurological outcome after acute ischemic stroke. Considering the “recanalization hypothesis,” which states that the reopening of occluded vessels can save threatened ischemic tissues, faster restoration of cerebral tissue blood flow is associated with better neurological recovery. Therefore, therapeutic strategies to increase the rate and speed of arterial recanalization, without increasing the risk of hemorrhagic complications, are the mainstay of patient treatment and future investigations.

Ultrasound energy has been demonstrated to facilitate activity of fibrinolytic agents, a process known as ultrasound-enhanced thrombolysis, contributing to augmentation of fibrinolysis and arterial recanalization. Recently, microbubble sonothrombolysis without tPA has been shown to effectively decrease infarct volumes and occurrence of intracranial hemorrhages in an experimental model of stroke.

The objective of the present study is to review randomized clinical studies regarding ultrasound-enhanced thrombolysis in patients with acute ischemic stroke.
Methods

The PubMed database was searched to identify papers published between January 1996 and July 2011 that addressed studies regarding ultrasound-enhanced thrombolysis for acute ischemic stroke in humans. The following search terms were used: “ultrasound-enhanced thrombolysis,” “sonothrombolysis,” “ultrasound and thrombolysis,” “ultrasound and tissue plasminogen activator,” “transcranial Doppler and thrombolytic therapy,” “transcranial color-coded duplex and thrombolytic therapy,” and “transcranial low-frequency ultrasound and thrombolytic therapy.” The reference lists of retrieved articles were also searched. The inclusion criterion was randomized studies on thrombolytic therapy using tPA and ultrasound. Exclusion criteria were as follow: 1) case reports and small case series; 2) nonrandomized studies; 3) investigations using intraarterial tPA, those using intraarterial infusion of microspheres using transforaminal insonation for vertebrobasilar circulation, or those using other thrombolytic agents; 4) abstracts of studies presented at international meetings; 5) randomized studies that included patients who had been previously reported on in other articles from the same institution; and 6) studies comprising experimental animal models.

Data extraction was performed based on ultrasound variables (ultrasound technology, frequency of the ultrasound waves, emitted-power output, ultrasound wave mode, and duration of thrombus exposure to ultrasound energy), patient characteristics (sample size, age, neurological status, affected arterial territory, interval from symptom onset to treatment), and outcome variables (rate of asymptomatic and symptomatic intracranial hemorrhagic complications, and of partial and complete arterial recanalization).

Two reviewers (E.B.S.S. and R.C.N.) independently selected the studies and extracted the data; disagreement between the 2 reviewers was resolved by a third independent reviewer (E.G.F).

Results

There have been 6 randomized controlled trials of sonothrombolysis associated with tPA for acute ischemic stroke. Two studies were excluded (one consisted of a pilot study with 3 patients in the control arm, and the other was published as an abstract). We did not find any randomized study addressing the effects of low-frequency transcranial ultrasound on thrombolysis. Although opinions can diverge (a recent meta-analysis has considered the TRUMBI study as a randomized controlled trial), we have considered the design of the TRUMBI study as nonrandomized because patients were alternately allocated to standard therapy (tPA alone) and combined therapy (low-frequency ultrasound plus tPA).

Ultrasound Variables Adopted in the Selected Trials

Two studies evaluated the effects of TCD ultrasonography on thrombolysis, and the remaining two evaluated the TCCD technology. The TCD ultrasoundography studies used 2-MHz pulsed ultrasound waves, while TCCD ultrasonography studies used 2-MHz and 1.8-Mhz pulsed waves (1 study each). The duration of thrombus exposure to ultrasound energy varied from 60 to 120 minutes. Ultrasound variable data of the studies are shown in Table 1.

Characteristics of the Included Trials

The TCCD ultrasonography studies were composed of a target group (TCCD ultrasound energy plus tPA) and a control group (only tPA). One TCD ultrasonography study consisted of a target group receiving TCD ultrasound energy plus tPA, and a control group receiving only tPA; another TCD ultrasonography study had a target group receiving TCD ultrasound energy plus tPA plus microspheres, and a control group receiving only tPA. Sample sizes, mean ages, median NIHSS scores, affected arterial territories, and the interval between symptom onset and treatment are detailed in Table 2.

Outcome Measures

Symptomatic intracranial hemorrhages were defined as intracranial hemorrhage appearing on CT scans within 72 hours or within 36 hours from symptom onset associated with neurological deterioration (an increase in NIHSS score of ≥ 4 points). Arterial recanalization was graded by the TIBI (Thrombolysis in Brain Ischemia) flow criteria (Score 2 or 3, partial recanalization; Score 4 or 5, complete recanalization). Safety and efficacy outcomes are summarized in Table 3.

Among the identified studies, the incidence of asymptomatic intracranial hemorrhage ranged from 9% to 21% in the sonothrombolysis group and from 0% to 11% in the control group. In contrast, symptomatic intracranial hemorrhages occurred in 0%–27% of the cases in the sonothrombolysis group, and in 0%–5% of the patients in the control group. All intracranial hemorrhages were associated with thrombolytic therapy. There were no differences in intracranial hemorrhage rates (asymptomatic and symptomatic hemorrhages) between the sonothrombolysis and control groups of the studies, except for 1 study reporting microsphere dose escalation in which a statistically significant increased rate of symptomatic intracranial hemorrhage was noticed in patients who underwent TCD ultrasonography combined with both tPA and 2.8 ml microspheres; in this subgroup 3 patients died (2 deaths were attributed to symptomatic intracranial hemorrhage). Concerning a TCCD ultrasonography study, 3 patients (15.8%) from the sonothrombolysis group and 2 patients (11.8%) from the control group died of space-occupying infarction and symptomatic intracranial hemorrhage. Craniotomy was performed in 1 patient in the sonothrombolysis group due to space-occupying infarction and symptomatic intracranial hemorrhage.

Complete arterial recanalization rates varied from 15% to 67% in the sonothrombolysis group and from 11% to 33% in the control group. Two studies, one using TCD ultrasonography and the other using TCCD ultrasonography, demonstrated that patients treated with ultrasound energy in association with tPA had statistically significantly higher rates of both complete recanalization and neurological improvement than those treated with tPA only. In a TCD ultrasonography study, complete recana-
Ultrasound-enhanced thrombolysis

**TABLE 1: Ultrasound variables in randomized studies of sonothrombolysis***

<table>
<thead>
<tr>
<th>Authors &amp; Year</th>
<th>Ultrasound Technology</th>
<th>Frequency (MHz)</th>
<th>Emitted-Power Output (mW/cm²)</th>
<th>Mode</th>
<th>Duration of Insonation (mins)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eggers et al., 2003</td>
<td>TCCD</td>
<td>2–4</td>
<td>179</td>
<td>pulsed</td>
<td>60</td>
</tr>
<tr>
<td>Alexandrov et al., 2004</td>
<td>TCD</td>
<td>2</td>
<td>&lt;750</td>
<td>pulsed</td>
<td>120</td>
</tr>
<tr>
<td>Eggers et al., 2008</td>
<td>TCCD</td>
<td>1.8</td>
<td>179</td>
<td>pulsed</td>
<td>60</td>
</tr>
<tr>
<td>Molina et al., 2009</td>
<td>TCD</td>
<td>2</td>
<td>NR</td>
<td>pulsed</td>
<td>90</td>
</tr>
</tbody>
</table>

* NR = not reported.

**TABLE 2: Characteristics of the patients in randomized clinical trials of sonothrombolysis***

<table>
<thead>
<tr>
<th>Authors &amp; Year</th>
<th>Target Group†</th>
<th>No. of Cases (target vs control)</th>
<th>Mean Age (yrs)‡</th>
<th>Median NIHSS Score (range)</th>
<th>Occluded Artery</th>
<th>Symptom Onset to Treatment (hrs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eggers et al., 2003</td>
<td>TCCD + tPA</td>
<td>11 vs 14</td>
<td>61 ± 9</td>
<td>18 (9–25)</td>
<td>MCA (M1)</td>
<td>≤3</td>
</tr>
<tr>
<td>Alexandrov et al., 2004</td>
<td>TCD + tPA</td>
<td>63 vs 63</td>
<td>69 ± 13</td>
<td>16 (4–34)</td>
<td>MCA</td>
<td>≤3</td>
</tr>
<tr>
<td>Eggers et al., 2008</td>
<td>TCCD + tPA</td>
<td>19 vs 18</td>
<td>61 ± 10</td>
<td>17.5 (12–23)</td>
<td>MCA (M1)</td>
<td>≤3</td>
</tr>
<tr>
<td>Molina et al., 2009</td>
<td>TCD + tPA + μS</td>
<td>12 (1.4 ml μS), 11 (2.8 ml μS) vs 12</td>
<td>65 ± 14</td>
<td>12 (4–21)</td>
<td>MCA, PCA</td>
<td>≤3</td>
</tr>
</tbody>
</table>

* μS = microspheres; MCA = middle cerebral artery; PCA = posterior cerebral artery.
† In all studies, the control group received only tPA.
‡ Values are presented as means ± SDs.

Issues related to instrumentation in ultrasonography are of fundamental importance to interpret the studies regarding sonothrombolysis in acute ischemic stroke. The following 3 different ultrasound modalities were used to increase the thrombolytic activity of tPA: TCD ultrasonography, TCCD ultrasonography, and therapeutic transcranial low-frequency ultrasonography. These devices generate ultrasound beams that differ greatly in acoustic properties, such as frequency, mechanical index, and the amount of brain tissue included in the beam (that is, areas of the brain exposed to ultrasound energy). Transcranial Doppler ultrasonography equipped with a 2-MHz transducer has been widely used for evaluating patients with acute ischemic stroke, traumatic brain injury, and aneurysmal subarachnoid hemorrhage. This nonimaging and hand-held ultrasonography examination device provides real-time blood flow velocity from cerebral arteries that can indicate arterial occlusion or recanalization, embolization, functional status of collateral circulatory pathways, and blood steal phenomenon. For diagnostic purposes, the emitted-power output is usually set at the maximal achievable level below the allowed limit of 720 mW with selected insonation deaths, and the sample volumes, or gates of insonation, are set at 3–6 mm for power motion Doppler devices and 10–15 mm for other single channel devices. While using TCD ultrasonography to monitor tPA thrombolysis, Alexandrov et al. incidentally suspected the ability of TCD ultrasonography to facilitate arterial recanalization in patients with acute ischemic stroke treated with intravenous tPA, a phenomenon confirmed afterward by the CLOTBUST (Combined Lysis of Thrombus in Brain ischemia using transcranial Ultrasound and Systemic tPA) trial. When signs of arterial occlusion are detected, the TCD ultrasound beam can be continu-
ously focused at the presumed thrombus location, allowing
both sonothrombolysis and continuous monitoring of
the recanalization process. Unfortunately, this method is
highly dependent on the skill of the TCD ultrasonography
operator. It is unrealistic to expect that an unskilled TCD
ultrasonography clinician can develop skills for a rapid
and accurate location of cerebral arterial occlusions.4,27,28

Transcranial color-coded duplex is another ultrasound
method that, like TCD ultrasonography, provides real-time
blood flow dynamics of cerebral arteries. However, unlike
TCD technology, TCCD transducers generate multiple
small ultrasound beams at dual emitting frequencies, one
for gray scale imaging and another for Doppler imaging;
hence, besides assessment of cerebral hemodynamics, this
technology can also afford both arterial location on color
flow imaging and imaging of the brain on B-mode ultra-
sonography.5,8,27,28 The TCCD ultrasound beam includes a
larger brain area (a greater amount of brain tissue is ex-
posed to ultrasound energy) compared with the more focal
TCD ultrasound beam. Among the limitations of TCCD
ultrasonography, there are no head frames for transducer
fixation (recanalization monitoring is carried out using
handheld probes), the mechanical index (an indicator of the
likelihood of mechanical biological effects, that is, stream-
ing and cavitation) of the TCCD ultrasonography is higher
than that for TCD ultrasonography, and no dose escalation
study has been performed to determine the levels of ultra-
sound intensity needed to enhance thrombolysis without
risks.27,28

Therapeutic transcranial low-frequency ultrasonog-
raphy is a nonimaging and nondiagnostic ultrasound
technology equipped with a transducer composed of 4
elements arranged in a diamond pattern. This technology
uses unfocused, low-frequency ultrasound (300 ± 1.5 kHz
to avoid standing waves), a temporal average spatial peak
intensity of 700 mW/cm², an average temporal pressure
less than 1 atmosphere (< 101 kPa for avoiding cavita-
tion), a mechanical index less than 0.2, a thermal index
in soft tissue less than 0.5, and a cranial thermal index of
approximately 4. The higher cranial thermal index was
addressed through the use of a cooling pad and a ther-
mal sensor to detect excessive heating. To decrease the
thermal effects, ultrasound is emitted in a pulsed fashion
with a 5% duty cycle and a pulse repetition frequency of
100 Hz (cycle/pulse ratio of 225). Despite leading to a
higher rate of recanalization, this method sonicates the
vessels and brain nonspecifically. The TRUMBI trial was
stopped because intracranial hemorrhages were frequent-
ly found, even in areas unaffected by ischemia.13,27,28 The
development of high-intensity, focused ultrasound with
MR imaging guidance may minimize hemorrhagic com-
plications in the future.

A recent comprehensive review and meta-analysis has
assessed the safety and efficacy of ultrasound-enhanced
tPA thrombolysis in the treatment of patients with acute
ischemic stroke.29 Taking into account 6 randomized (com-
prising 224 patients) and 3 nonrandomized (comprising 192
patients) studies, the authors concluded that sonothrom-
bolysis using TCD or TCCD ultrasonography appears to
be safe and leads to higher rates of complete recanaliza-
tion when compared with intravenous tPA thrombolysis.
Ultrasound-enhanced thrombolysis

Sonothrombolysis using TCD or TCCD ultrasonography, with or without microspheres, is associated with a nearly 3-fold increased likelihood of complete recanalization and an approximately 2-fold higher likelihood of functional independence at 3 months. We stressed that this meta-analysis included randomized and nonrandomized studies, as well as abstracts of studies presented at international meetings, and focused on quantitative analysis of them, without taking into consideration ultrasound variables such as type of ultrasound technology, frequency of ultrasound waves, emitted power output, ultrasound wave mode, and duration of thrombus exposure to ultrasound energy, while our manuscript focused on qualitative analysis of Class I evidence studies, classifying them in terms of ultrasound variables, presence of microspheres, sample characteristics, and outcome measures. Although both reviews have provided similar findings (that is, ultrasound-enhanced thrombolysis seems to be a safe procedure and is associated with a significantly higher rate of arterial recanalization in acute ischemic stroke), our study revealed that only 2 randomized controlled studies, one using TCD and the other using TCCD, support these conclusions.

Ultrasound energy has been experimentally demonstrated to improve the thrombolytic effects of tPA. The mechanisms of action are still under debate; however, there is evidence of at least 4 contributing effects as follows: 1) rectified diffusion, which provides a pumping effect to transport drugs into the thrombus; 2) reformation and opening of the fibrin matrix under ultrasound exposure, which enhances drug diffusion; 3) cleaving of fibrin polymers to extend the surface for thrombolytic interaction; and 4) improvement of binding of recombinant tPA to fibrin. Concerning the frequency range used for diagnostic ultrasound examinations, the mechanical pressure wave of the ultrasound energy propagates through the tissues, induces fluid motion, and helps tPA to reach the binding sites. In addition, 2-MHz ultrasound waves enhance tPA-thrombus dissolution by fluid streaming around the clot surface and disaggregation of fibrin fibers, which results in a greater amount of binding sites for tPA without heating or cavitation. In stroke patients treated with tPA, intravenous infusion of microbubbles or microspheres has been proved to accelerate clot lysis during 2-MHz ultrasound monitoring, by transmitting energy momentum from an ultrasound wave to residual flow. These mechanisms support the findings of sonothrombolysis in the clinical setting.

Conclusions

Despite the limitations of the included studies, there is evidence that sonothrombolysis associated with tPA with frequencies and energy intensities in a range of diagnostic ultrasound devices is safe and results in an increased rate of arterial recanalization in acute ischemic stroke. Future studies should focus on the development of the following: 1) microspheres associated with ultrasound for augmenting brain perfusion and drug delivery within the penumbra area; 2) an operator-independent ultrasound device that can be used by medical personnel irrespective of experience with TCD or TCCD ultrasound examinations; 3) intraarterial ultrasound devices for thrombolysis; and 4) ultrasound catheters for minimally invasive evacuation of intracranial hematoma as a complication of thrombolytic therapy or other causes. In the near future, it is possible that high-intensity focused ultrasound neurosurgery for brain tumors, Parkinson disease, epilepsy, and other conditions may become a reality.

Disclosure

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author contributions to the study and manuscript preparation include the following. Conception and design: Bor-Seng-Shu, Nogueira, Figueirêdo. Acquisition of data: Bor-Seng-Shu, Nogueira, Figueirêdo. Analysis and interpretation of data: all authors. Drafting the article: Bor-Seng-Shu, Nogueira. Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Bor-Seng-Shu. Administrative/technical/material support: Teixeira. Study supervision: Teixeira.

References

11. Culp WC, Flores R, Brown AT, Lowry JD, Roberson PK,

Manuscript submitted September 15, 2011. Accepted October 31, 2011. Please include this information when citing this paper: DOI: 10.3171/2011.10.FOCUS11251. Address correspondence to: Edson Bor-Seng-Shu, M.D., Ph.D.,Rua Loefgreen, 1272, CEP 04040-001, Sao Paulo, SP, Brazil. email: edsonshu@hotmail.com.